Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Studied

Phase 3 randomized trial comparing two tirzepatide doses with placebo for weight management.

Who / model

938 adults with overweight or obesity and type 2 diabetes, treated for 72 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Average weight fell 12·8% and 14·7% with the studied doses versus 3·2% with placebo. At least 5% weight loss occurred in 79 to 83% versus 32%, meeting both primary outcomes. Digestive adverse events were most frequent. Serious adverse events affected 7% overall; two deaths occurred in the lower-dose group and were judged unrelated to treatment by investigators.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary